SCHEMBL13969656

SCHEMBL13969656

CCOS(=O)(=O)c1cccc([N+](=O)[O-])c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.64
WDR77 Q9BQA1 1/20 0.64
KMT2A Q03164 4/20 0.60
GAA P10253 1/20 0.60
HTT P42858 1/20 0.60
CA2 P00918 2/20 0.57
CA5A P35218 1/20 0.57
CA1 P00915 1/20 0.56
MMP1 P03956 1/20 0.56
MMP2 P08253 1/20 0.56
MMP9 P14780 1/20 0.56
MMP8 P22894 1/20 0.56
MMP13 P45452 1/20 0.56
MAPT P10636 2/20 0.56
MEN1 O00255 2/20 0.55
LMNA P02545 3/20 0.52
ALDH1A1 P00352 2/20 0.51
F2 P00734 2/20 0.50
PRSS1 P07477 2/20 0.50
PRSS2 P07478 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8266069 0.88 PRMT5 (0.59) PRMT5WDR77KMT2AGAAHTT
SCHEMBL8264853 0.88 PRMT5 (0.61) PRMT5WDR77KMT2AGAAHTT
SCHEMBL6114507 0.87 PRMT5 (0.68) PRMT5WDR77KMT2AGAAHTT
SCHEMBL25725225 0.84 PRMT5 (0.60) PRMT5WDR77KMT2AGAAHTT
SCHEMBL1317032 0.82 KMT2A (0.66) PRMT5WDR77KMT2AGAAHTT
SCHEMBL27767684 0.82 PRMT5 (0.61) PRMT5WDR77KMT2AGAAHTT
SCHEMBL4456811 0.82 CA1 (0.50) CA2CA5ACA1MMP1MMP2
SCHEMBL27546340 0.81 PRMT5 (0.57) PRMT5WDR77KMT2AGAAHTT
SCHEMBL14075589 0.81 PRMT5 (0.57) PRMT5WDR77KMT2AGAAHTT
SCHEMBL8267239 0.81 PRMT5 (0.57) PRMT5WDR77KMT2AGAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3704120-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS Jubilant Episcribe LLC (US) 2020-09-09 EP disclosed
WO-2019102494-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2019-05-31 WO disclosed
US-20090023791-A1 PH-dependent NMDA receptor antagonists EMORY UNIVERSITY (US) 2009-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023791-A1 PH-dependent NMDA receptor antagonists GRIN1, GRIA4, GRIA1 PRMT5 1707/4885WDR77 3242/4885KMT2A 259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.